We previously reported that Crenolanib, a PDGFR inhibitor currently used in clinical trials to treat GBM, induced apoptosis at the same extent either in c-CSC1 or p-CSC1, circumventing the anti-Notch and anti-EGFR drug resistance. This evidence concerns the gene EGFR and glioblastoma.